9 recruiting, 8 completed, 4 active not recruiting, 4 terminated. 30 Phase 2, 11 Phase 1, 3 Phase 3.
Follow Prostatic Neoplasms, Castration-Resistant: new trials by email Literature Review of Prostatic Neoplasms, Castration-Resistant trials Research Report on Prostatic Neoplasms, Castration-Resistant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer TD001 - Metastatic Castration-Resistant Prostatic Cancer | Phase 1 / Phase 2 | Recruiting | T.O.A.D. Oncology SA | 180 | 2026-01-30 | 2026-05-29 |
| A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) JSB462, AAA617 - Prostatic Cancer, Castration-Resistant | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 138 | 2025-07-03 | 2026-10-09 |
| A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) Docetaxel, Ifinatamab Deruxtecan, Opevesostat - Castration-Resistant Prostatic Cancer, Metastasis | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 360 | 2025-07-03 | 2026-10-09 |
| Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) Opevesostat, Olaparib, Docetaxel - Prostatic Neoplasms, Castration-Resistant | Phase 1 / Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 220 | 2024-05-20 | 2026-10-29 |
| Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients. Xtandi, Zytiga® (Abiraterone Acetate), SBRT - Prostatic Neoplasms, Castration-Resistant | Phase 2 | Recruiting | Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic | 51 | 2024-05-16 | 2026-07-21 |
| Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer Gedatolisib, Darolutamide - mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male | Phase 1 / Phase 2 | Recruiting | Celcuity Inc | 54 | 2024-01-01 | 2026-04-13 |
| A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer lorigerlimab, docetaxel, Prednisone - Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms | Phase 2 | Completed | MacroGenics | 154 | 2023-09-28 | 2026-05-22 |
| HTL0039732 in Participants With Advanced Solid Tumours HTL0039732 Capsules, HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusion - Neoplasms, Prostatic Neoplasms, Castration-Resistant | Phase 1 / Phase 2 | Recruiting | Cancer Research UK | 150 | 2023-08-02 | 2026-10-01 |
| A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine - Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer | Phase 2 | Terminated | MacroGenics | 192 | 2023-06-13 | 2026-02-09 |
| Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC Patient-specific adaptive therapy, Abiraterone acetate, Enzalutamide - Prostatic Neoplasms, Castration-Resistant | Phase 2 | Recruiting | Leiden University Medical Center | 168 | 2022-11-10 | 2024-11-26 |
| Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC NUV-422, Enzalutamide - Prostate Cancer, Prostatic Cancer | Phase 1 / Phase 2 | Withdrawn | Nuvation Bio Inc. | 2022-09-01 | 2022-08-05 | |
| Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer Docetaxel intermittent - Castration Resistant Prostatic Cancer | Phase 2 | Terminated | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 6 | 2022-07-29 | 2024-11-22 |
| A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer BMS-986218, Docetaxel, Nivolumab - Prostatic Neoplasms, Castration-Resistant | Phase 2 | Terminated | Bristol-Myers Squibb | 10 | 2022-02-14 | 2025-06-10 |
| TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone - Prostatic Neoplasms, Castration-Resistant, Drug Therapy, Combination | Phase 2 | Unknown | West China Hospital | 30 | 2022-01-01 | 2021-12-14 |
| A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours HMBD-001, HMBD-001 and enzalutamide - Bladder Cancer, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Cancer Research UK | 81 | 2021-11-10 | 2025-08-11 |
| 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) 64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA - Prostatic Neoplasms, Castration-Resistant | Phase 1 / Phase 2 | Recruiting | Clarity Pharmaceuticals Ltd | 54 | 2021-08-11 | 2026-05-06 |
| Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer Omeprazole 80 mg twice daily - Prostate Cancer, Refractory Cancer | Phase 2 | Recruiting | Wake Forest University Health Sciences | 50 | 2021-03-05 | 2026-04-13 |
| Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer Ipilimumab, Nivolumab - Prostatic Neoplasms, Castration-Resistant | Phase 2 | Completed | Radboud University Medical Center | 69 | 2021-01-19 | 2026-01-06 |
| Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer Etrumadenant, Zimberelimab, Quemliclustat - Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms | Phase 1 / Phase 2 | Completed | Arcus Biosciences, Inc. | 173 | 2020-07-07 | 2025-07-22 |
| Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC) Darolutamide (Nubeqa, BAY1841788), Enzalutamide - Prostatic Cancer, Castration-Resistant | Phase 2 | Terminated | Bayer | 30 | 2019-12-17 | 2023-08-04 |
Showing 20 of 30. Sign in to see all of them.
Prostatic Neoplasms (11) · Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Endometrial Neoplasms (2) · Esophageal Neoplasms (2) · Melanoma (2) · Mesothelioma, Malignant (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Stomach Neoplasms (2) · Urinary Bladder Neoplasms (2) · Uterine Cervical Neoplasms (2) · Anus Neoplasms (1) · Carcinoma, Hepatocellular (1)
Genital Diseases (30) · Genital Neoplasms, Male (30) · Urogenital Diseases (30) · Urogenital Neoplasms (30) · Genital Diseases, Male (29) · Male Urogenital Diseases (29) · Neoplasms by Site (29) · Prostatic Diseases (29) · Neoplasms (27) · Prostatic Neoplasms (19) · Lung Diseases (4) · Neoplasms, Glandular and Epithelial (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4)
enzalutamide (10) · Abiraterone Acetate (6) · Docetaxel (5) · Prednisone (4) · abiraterone (4) · Nivolumab (2) · apalutamide (2) · cabazitaxel (2) · darolutamide (2) · CTLA-4 Antigen (1) · Dexamethasone (1) · Drug Therapy (1) · Ipilimumab (1) · Omeprazole (1) · Pluvicto (1)
Michael Graham PhD, MD (3) · Cancer Research UK (2) · Janssen Research & Development, LLC (2) · MacroGenics (2) · Merck Sharp & Dohme LLC (2) · Novartis Pharmaceuticals (2) · Arcus Biosciences, Inc. (1) · Australian and New Zealand Urogenital and Prostate Cancer Trials Group (1) · Bayer (1) · Bristol-Myers Squibb (1) · British Columbia Cancer Agency (1) · Celcuity Inc (1) · Clarity Pharmaceuticals Ltd (1) · Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic (1) · Leiden University Medical Center (1)
United States (20) · Spain (10) · Australia (9) · France (9) · United Kingdom (9) · Canada (7) · Italy (7) · South Korea (6) · Poland (5) · Israel (4) · Netherlands (4) · Belgium (3) · Germany (3) · Taiwan (3) · Chile (2)
David Oh, MD (1) · Dr. Amy Rieborn (1) · Dr. Laurence Krieger, MBChB,FRACP (1) · Hao Zeng (1) · J C W, M.D,Ph.D (1) · Johann de Bono, Prof (1) · Kate Mahon (1) · Kim N Chi, MD (1) · Liudmila Schafer, M.D. (1)
PMID 33836265, PMID 40016438, PMID 42558019
2023 (3), 2017 (2), 2016 (1), 2025 (1), P30CA012197 (1), R01CA223484 (1)